DiscoverThe Weight Loss PodcastNovo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'
Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

Update: 2024-10-24
Share

Description

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'